ArticleMolecular biology reports2026
Downregulation of long non-coding RNAs PCAT18, HOTAIR, and CTBP1-AS in prostate malignancies.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionProstate cancer (PCa) ranks as the fifth most prevalent cancer type globally, with its incidence rising due to lifestyle changes. The prognosis significantly worsens at the metastatic stage, with a 5-year survival rate dropping to 30%.
aimsThis study focuses on the androgen signaling pathway's role in PCa etiology and aims to identify molecular mechanisms that could serve as potential biomarkers for early diagnosis of the disease in a population of Iranian men. MATERIALS AND
methodsWe analyzed the expression levels of long non-coding RNAs (lncRNAs) PCAT18, CTBP1 antisense RNA (CTBP1-AS), and HOTAIR in blood samples from 30 PCa patients and 30 individuals with benign prostatic hyperplasia (BPH). RT-PCR and specific primers were used for quantification.
resultsWe observed a significant downregulation of PCAT18, HOTAIR and CTBP1-AS in the PCa cohort compared to BPH. ROC curve analysis revealed HOTAIR as the most promising biomarker, with an area under the curve of 0.6897. Further analysis indicated that PCAT18 and HOTAIR demonstrate considerable sensitivity and specificity for distinguishing PCa from BPH, suggesting their potential utility in clinical diagnosis and prognosis evaluation. Significant correlation was found between LNCRNAs expression and demographic information for CTBP1-AS expression vs. size of tumor, PCAT18 expression vs. PSA and PCAT18 expression vs. grade. These results implying that lncRNAs dysregulation may be more indicative of cancer biology. DISCUSSION: These findings highlight the importance of CTBP1, PCAT18 and HOTAIR as potential biomarkers in prostate cancer and underscore the necessity for further investigation into their roles in cancer progression and therapeutic strategies.
Indexed as
Identifiers
42313281What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.